#### 505035666 08/03/2018

### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5082417

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
DR JOSEPH A F F	06/13/2016
DR SHIRISH A SHAH SHAH	05/16/2016
PRATIBHA S PILGAONKAR	06/10/2016
ANILKUMAR S GANDHI	06/07/2016

### **RECEIVING PARTY DATA**

Name:	EZRA PHARMA LLC
Street Address:	401 SOUTH CEDAR STREET
City:	LITTLE ROCK
State/Country:	ARKANSAS
Postal Code:	72205
Name:	RUBICON RESEARCH PRIVATE LIMITED
Street Address:	221, ANNEXE BUILDING
Internal Address:	GOREGAON-MULUND LINK ROAD, OFF L.B.S.
City:	BHANDUP (W), MUMBAI
State/Country:	INDIA
Postal Code:	400078

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	15633338

### **CORRESPONDENCE DATA**

**Fax Number:** (312)884-7352

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3124661033

patent@amintalati.com Email:

**Correspondent Name:** AMIN TALATI UPADHYE LLP

100 S. WACKER DRIVE Address Line 1:

Address Line 2: **SUITE 2000** 

Address Line 4: CHICAGO, ILLINOIS 60606

> **PATENT** REEL: 046551 FRAME: 0866

505035666

ATTORNEY DOCKET NUMBER:	EZRA-102-CON
NAME OF SUBMITTER:	GEORGE M. CARRERA, JR.
SIGNATURE:	/George M. Carrera, Jr./
DATE SIGNED:	08/03/2018

### **Total Attachments: 5**

source=Fix\_Assignment\_EZRA\_102#page1.tif source=Gandhi\_Assignment\_EZRA\_102#page1.tif source=Pilgaonkar\_Assignment\_EZRA\_102#page1.tif source=Shah\_Assignment\_EZRA\_102#page1.tif source=Shah\_Assignment\_EZRA\_102#page2.tif

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Dr. Joseph A. Fix – (hereinafter, the "Assignor") 100 Lawrence Avenue Lawrence, Kansas 66049 USA

acknowledges the payment by and receipt from

Ezra Pharma LLC – (the "Assignee") 401 South Cedar Street Little Rock, Arkansas 72205 USA

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

# EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY

which is/are described and/or claimed in a Non-Provisional application for Letters Patent of the United States, Serial Number 15/080,305 filed on March 24, 2016, executed by the Assignor and naming as inventor(s) Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, and Anilkumar S. Ghandi (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

	ASSIGNOR		ASSIGNEE – Ezra Pharma LLC			
Ву:	gapl Kaf A	.ccepted By:				
	Signature /		Signature			
	Dr. Joseph A. Fix		Michael Geranen, President			
	Printed Name		Printed Name and Title			
	13 JUNE 2016					
	Date		Date			

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Anilkumar S. Gandhi – (hereinafter, the "Assignor") 221, Annexe Building, Goregaon-Mulund Link Road Off L.B.S. Marg, Bhandup (W), Mumbal, 400078 India

acknowledges the payment by and receipt from

Rubicon Research Private Limited – (the "Assignee") 221. Annexe Building, Goregaon-Mulund Link Road Off L.B.S. Marg, Bhandup (W), Mumbai, 400078 India

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and transfers to and in: any and all invention(s) of U.S. Patent Application entitled

EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS

which is/are described and/or claimed in a Non-Provisional application for Letters Patent of the United States, Serial Number 15/080,305 filed on March 24, 2016, executed by the Assignor and naming as inventor(s) Joseph A. Pix, Shirish A. Shah, Pratibha S. Pilgaonkar, and Anilkumar S. Gandhi (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rights/of-teaths; and sw/bm testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

	ASSIGNOR	ASSIGNEE - Rubicon Research Private Limited				
3v:		Accepted By:				
·	Signature	Signature	****			
	Anilkumar S. Gandhi Printed Name	Practible S. Pilozonkar, Chief Executive Office —— Printed Name and Tide	SĽ			
	07 Jun 2016	10th June 2016				
	Date	Date				
		ivil <b>DATENT</b>				

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Pratibha S. Pilgaonkar — (hereinafter, the "Assignor") 221, Annexe Building, Goregaon- Mulund Link Road Off L.B.S. Marg, Bhandup (W), Mumbai, 400078 India

acknowledges the payment by and receipt from

Rubicon Research Private Limited – (the "Assignee") 221, Annexe Building, Goregaon- Mulund Link Road Off L.B.S. Marg, Bhandup (W), Mumbai, 400078 India

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

### EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS

which is/are described and/or claimed in a Non-Provisional application for Letters Patent of the United States, Serial Number 15/080,305 filed on March 24, 2016, executed by the Assignor and naming as inventor(s) Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, and Anilkumar S. Gandhi (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

ASSIGNOR		ASSIGNEE – Rubicon Research Private Limited				
By: 181-184— Signature		Accepted By:	PSO - E C			
Pratibha S. Pilgaonk Printed Name	car		Pratibha S. Pilgaonkar, Chief Executive Officer Printed Name and Title			
10th June	2016		10th June 2016			
Date		lofl	PATENT REEL: 046551 FRAME: 0870			

IN CONSIDERATION of the sum of One Dollar (\$1.00), and of other good and valuable consideration

the undersigned inventor

Dr. Shirish A. Shah – (hereinafter, the "Assignor") 2814 West Wildwood Drive Phoenix, Arizona 85045 USA

acknowledges the payment by and receipt from

Ezra Pharma LLC – (the "Assignee") 401 South Cedar Street Little Rock, Arkansas 72205 USA

wherein the undersigned Assignor sells, assigns, and transfers to Assignee his world-wide, entire, complete, and exclusive rights, title, and interest to and in: any and all invention(s) of U.S. Patent Application entitled

### EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY

which is/are described and/or claimed in a Non-Provisional application for Letters Patent of the United States, Serial Number 15/080,305 filed on March 24, 2016, executed by the Assignor and naming as inventor(s) Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, and Anilkumar S. Ghandi (the "Patent Application"); the Patent Application; any and all nonprovisional(s), continuation(s), division(s), renewal(s), substitute(s), reissue(s), reexamination(s), foreign application(s) including PCT application(s), or any other counterpart application(s) based in whole or in part on the Patent Application (collectively "Counterpart Non-Provisional Application(s)"); and any and all Letters Patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s) in the United States and in any other country or territory for the full term or terms for which said U.S. Letters Patent(s) and for which said foreign Letters Patent(s) may be issued or granted, including any extensions thereof.

Upon Assignee's request, Assignor agrees, at the expense of the Assignee, to promptly take such actions as may be reasonably necessary to vest, secure, perfect, protect, and/or enforce the rights and interests of Assignee as received by the Assignee by way of this Assignment. Such actions shall include, without limitation, the prompt execution and delivery of documents in recordable form (including the prompt execution and delivery of additional confirmatory assignments), information, rightful oaths, and sworn testimony useful or necessary for Assignee or its affiliates, designees, or agents to file, prosecute, or maintain any registration or application relating in part or in whole to the Patent Application, or to pursue or defend any administrative, court, or other legal proceeding involving any U.S. or foreign patent(s) granted on the Patent Application or granted on Counterpart Non-Provisional Application(s).

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

1 of 2

# IN WITNESS WHEREOF, this assignment has been executed by:

Si	ignature:	SI	48hed	<u>,                                     </u>						
Na	ame:	Dr. Shi	rish A. Shah							
Da	ate://	May	16,20	<u> 16</u>						
	_									
	F		)							
COUNTY	OF	Cook	)			,				
satisfactory executed the behalf of w	day of the above stay evidence to be the same in her which the person under PENA	be the person authorized on acted, ex	on whose named capacity, an accuted the ins	e is subscrib d that by he trument.	ed to the wi er signature	thin ins	trument a instrumer	and acknown the the pers	vledged to on, or the	me that he entity upon
oaragraph	is true and cor	rect.								
Nota	OFFICIAL SEAL JENNIFER L JALON Bry Public - State on mission Expires A	VEC If Illinois		WIT	NESS my h	and and	l official	seal		
(SEAL)			<b>-</b>	$\frac{\bigcirc}{\text{Sigr}}$	MM attire of N	otary P	<u>Jublic</u>	olc	<u>_</u>	
				Му	Commissic	on Expi	res:	07/201	9	